India Diclofenac Sodium Market to be Grow by CAGR of 4.27% during the forecast period
Growing cases of arthritis is expected to drive the
India Diclofenac Sodium Market in the forecast period 2027-2031
According to TechSci Research report, “India Diclofenac
Sodium Market - By Region, Competition, Forecast &
Opportunities, 2031F”, The India Diclofenac Sodium Market was
valued at USD 312.43 Million in 2025 and is expected to reach USD 398.41 Million
by 2031, growing with a CAGR of 4.27% in the forecast period.
The
India diclofenac sodium market represents a significant component of the
country’s pharmaceutical industry, driven by high demand for effective pain
management solutions across a broad population base. Diclofenac sodium, a
widely used non-steroidal anti-inflammatory drug (NSAID), is commonly employed
to treat conditions such as arthritis, back pain, sprains, musculoskeletal
injuries, and other inflammation-related disorders. The market benefits from
India’s large and growing geriatric population, which is more prone to chronic
joint pain and inflammatory conditions. In addition, rising sedentary
lifestyles, increasing cases of obesity, and a surge in physical stress-related
ailments among working adults have contributed to the sustained demand for diclofenac-based
medications.
Tablets continue to dominate the market, offering a cost-effective, easily transportable, and fast-acting option for systemic pain relief. However, there is a growing shift toward topical formulations such as gels, sprays, and patches due to their reduced side effect profile and preference among elderly patients for localized treatment. The over-the-counter (OTC) availability of diclofenac in topical forms supports self-medication, particularly in semi-urban and rural areas where medical consultation may be limited. Injections, though less commonly used, are prescribed in clinical settings for acute pain or post-surgical inflammation.
North India leads regional demand due to its dense population, higher incidence of pain-related conditions, and stronger pharmaceutical manufacturing and distribution infrastructure. States like Uttar Pradesh, Punjab, Delhi, and Rajasthan contribute significantly to market revenues. Online pharmacies and organized retail chains have expanded product access across remote regions, supporting the sale of both branded and generic diclofenac products. E-pharmacy growth is also reshaping the market landscape by offering patients easier access, better pricing, and timely refills, especially for chronic users.
India’s pharmaceutical manufacturing strength plays a central role in the dominance of in-house production. Domestic companies benefit from cost advantages, skilled labor, and supportive government policies encouraging local manufacturing under initiatives like "Make in India." In-house production allows companies to control quality, ensure regulatory compliance, and meet both domestic and export demand efficiently.
Despite the market’s strong fundamentals, there are challenges. Long-term use of diclofenac sodium is associated with side effects such as gastrointestinal issues, liver and kidney complications, and increased cardiovascular risks. These concerns have led to more cautious prescribing by healthcare professionals. Environmental concerns also persist, especially due to diclofenac’s known impact on vulture populations when used in veterinary applications. This has resulted in regulatory restrictions on non-human use and increased scrutiny of manufacturing and distribution practices.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Diclofenac Sodium Market ”
The India Diclofenac Sodium Market is segmented into product
type, form, application, route of administration, source, distribution channel,
end user, regional distribution, and company.
Based on route of administration, In the India
diclofenac sodium market, oral formulations are the dominant segment among
oral, intravenous, topical, and other forms. Oral diclofenac, primarily in
tablet form, is widely used due to its effectiveness in managing a range of
moderate to severe pain conditions, including arthritis, musculoskeletal
disorders, and post-operative inflammation. These formulations are easy to
administer, cost-effective, and broadly available through both retail and
online pharmacies.
Oral diclofenac offers systemic relief, making it
suitable for chronic conditions that require long-term management. Patients and
physicians are familiar with its usage, leading to its continued preference
despite the growing awareness of potential side effects. Its over-the-counter
availability in certain strengths has further driven widespread consumption,
especially in semi-urban and rural areas where medical guidance may be limited.
Topical formulations are gaining popularity for
localized pain relief, particularly among the elderly, due to fewer systemic
side effects. Intravenous forms are limited to hospital use and acute care
settings. However, due to convenience, affordability, and broader therapeutic
application, oral diclofenac remains the most dominant form in the Indian
market.
Based on source,
in the India diclofenac sodium market, in-house manufacturing was the
dominant mode of production compared to Contract Manufacturing Organizations
(CMOs). This dominance is primarily due to India's strong domestic
pharmaceutical industry, which includes numerous well-established companies
with integrated manufacturing capabilities. These companies prefer to produce
diclofenac sodium and other essential medications in-house to maintain strict
control over quality, production timelines, and regulatory compliance.
In-house
manufacturing allows for cost efficiency, particularly in bulk production,
which is crucial for a high-demand, price-sensitive market like India. It also
enables faster product development, customization of formulations, and quicker
response to market changes. The ability to meet both domestic and export demand
without dependency on external partners gives pharmaceutical firms a strategic
advantage. Government policies encouraging self-reliance, such as the
"Make in India" initiative and support for Active Pharmaceutical
Ingredient (API) production, further promote in-house operations. While CMOs
are used for scalability and capacity overflow, in-house manufacturing
continues to lead due to its control, flexibility, and alignment with long-term
business and export strategies.
Based on region, South India is currently the
fastest-growing region in the diclofenac sodium market in India. This growth is
driven by a combination of rising healthcare awareness, improved access to
medical facilities, and an increasing burden of chronic pain conditions such as
arthritis, back pain, and inflammatory disorders. States like Tamil Nadu,
Karnataka, Andhra Pradesh, and Kerala have seen rapid urbanization, a growing
elderly population, and lifestyle-related health issues, all of which
contribute to higher demand for effective pain management solutions like
diclofenac sodium.
The region has a strong network of hospitals, retail
pharmacies, and a rapidly expanding base of e-pharmacy users, which facilitates
wider distribution and accessibility of both prescription and over-the-counter
diclofenac formulations. Topical products are gaining popularity among elderly
users due to their ease of use and lower risk of systemic side effects.
South India also benefits from a robust pharmaceutical
manufacturing ecosystem, particularly in Tamil Nadu and Telangana, which
supports supply chain efficiency. Rising healthcare spending, patient
awareness, and digital adoption make South India a key driver of future growth
in the diclofenac sodium market.
Major companies operating in India Diclofenac
Sodium Market are:
·
Novartis India Ltd.
·
Hetero Drugs Ltd.
·
Auro Laboratories
Ltd.
·
Aarti Drugs Ltd.
·
J B Chemicals and
Pharmaceuticals Ltd.
·
Novartis India Ltd.
·
Emkay Pharma Pvt.
Ltd.
·
Bestochem
Formulations (India) Limited
·
Salvavidas
Pharmaceutical Pvt. Ltd.
·
Wellona Pharma Pvt.
Ltd.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The India diclofenac sodium market is a vital segment
of the country's pain management drug landscape, characterized by high demand
due to the growing incidence of joint disorders, chronic inflammation, and
injuries. Widely used in both prescription and over-the-counter formats,
diclofenac sodium is available in tablets, gels, injections, and sprays. The
market benefits from strong domestic manufacturing capabilities and widespread
retail and e-pharmacy networks. Increasing awareness about pain management, expanding
healthcare access, and rising preference for topical formulations are shaping
market dynamics. Despite regulatory and safety challenges, consistent demand
across urban and rural regions ensures steady growth for diclofenac-based
products in India” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“India Diclofenac Sodium Market By Product Type (Prescription v/s OTC),
By Form (Tablet, Injection, Gel, Others), By Application (Osteoarthritis,
Ankylosing Spondylitis, Dysmenorrhea, Rheumatoid arthritis, Migraine, Pain and
Others), By Route of Administration (Oral, Intravenous, Topical, Others), By
Source (In-house v/s Contract Manufacturing Organizations), By Distribution
Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Region, Competition, Forecast & Opportunities, 2021-2031F”,
has evaluated the future growth potential of India Diclofenac Sodium Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India Diclofenac
Sodium Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com